Saratov JOURNAL of Medical and Scientific Research
Home

The combined using of ustekinumab and narrow-band phototherapy in treatment of severe psoriasis

Year: 2015, volume 11 Issue: №3 Pages: 385-389
Heading: Dermatovenerology Article type: Short message
Authors: Kruglova L.S., Ponich E.S., Babushkin A.M.
Organization: BU Khanty-Mansi Autonomous District— Yugra «Khanty-Mansi clinical skin and venereologic dispensary», Moscow Scientific and Practical Center of Dermatology, Venereology and Cosmetology of Moscow City Health Department
Summary:

Aim: research the effectiveness of UVB 311 nm phototherapy in patients with the "escape effect" that developed in the 44th — 56th weeks of the ustekinumab use. Materials and Methods. The examination and treatment of 9 patients with extensive psoriasis vulgaris receiving ustekinumab by hypodermic injection at a dose of 45 mg if body weight of the patient not more than 100 kg, and 90 mg of body weight over than 100 kg, on the zero week, the 4th week and then every 12 weeks. Among them 6 (66,7%) men and 3 (33,3%) women aged from 28 to 65 years. All patients in the 44th — 56th weeks of ustekinumab observed effect of "escape" in connection with which he has been appointed narrowband phototherapy. Results. The combined use of ustekinumab and UVB 311 nm phototherapy in patients with "escape effect" contributes to the marked regression of clinical symptoms and allows you to control the process for long, which is confirmed by the dynamics of the index PASI, BSA and DLQI. Conclusion. In the case of the effect of "escape" in the application of biological therapy drugs (ustekinumab) possible appointment of a narrow-band medium wave phototherapy course 25-30 procedures.

Keywords: BSA, narrow-band phototherapy, PASI, psoriasis, quality of life, ustekinumab

Bibliography:
1. Kurd SK, Gelfand JM. The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003-2004. J Am Acad Dermatol 2009; 60 (2): 218-224
2. Pathirana D, Ormerod AD, Saiag P, et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 2009; 23 (Suppl 2): 1-70
3. Dommasch ED, Abuabara K, Shin DB, et al. The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-anal-ysis of randomized controlled trials. J Am Acad Dermatol 2011; 64(6): 1035-1050
4. Doherty SD, van voorhees A, Lebwohl MG, et al. National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents. J Am Acad Dermatol 2008; 59 (2): 209-217
5. Tsai TF, Ho V, Song M, et al. The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection. Br J Dermatol 2012; 167(5): 1145-1152
6. Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008; 371 (9625): 1665-1674
7. Papp KA, Langley RG, Lebwohl M, Krueger GG, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX). Lancet. 2008; 371 (9625): 1675-1684
8. Pathirana D, Ormerod AD, Saiag P, et al. European S3-Guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venerol 2009; 23 (2): 1-70
9. Krutmann J, Elmets CA. Phototherapy of psoriasis update with practical pearls. J Cutan Med 2002; 6 (3): 721-723
10. Parsed D, Kanwar A, Kumar B. Phototherapy (UVB and PUVA) in the treatment of psoriasis. J EADV 2006; 20 (2): 175-177.

AttachmentSize
2015_03-01_385-389.pdf350.87 KB
All articles of the authors: Babushkin A.M. , Kruglova L.S. , Ponich E.S.

No votes yet